IONS Form 144 lists proposed sale of restricted shares

IONS filed a Form 144 notice reporting proposed sales of Common Stock tied to restricted equity awards.

Rhea-AI Filing Summary

IONS filed a Form 144 notice reporting proposed sales of Common Stock tied to restricted equity awards. The notice lists specific grant dates and share counts for restricted stock: 3,110 (01/15/2022), 1,861 (01/15/2021), 1,956 (01/15/2023), 1,900 (02/23/2023) and 1,775 (02/01/2024).

Insights

Corporate Counsel

Form 144 is a notice of proposed affiliate sales; this excerpt lists restricted stock awards and share counts.

The filing lists multiple restricted stock grant dates and share quantities associated with equity compensation. It records planned dispositions by an affiliate under Form 144 procedures rather than completed open‑market trades.

Timing and proceeds treatment are not stated in the excerpt; subsequent filings would show execution details if sales occur.

Key Figures

Restricted stock — 01/15/2022: 3,110 shares Restricted stock — 01/15/2021: 1,861 shares Restricted stock — 01/15/2023: 1,956 shares +2 more

5 metrics

Restricted stock — 01/15/2022 3,110 shares grant date <date>01/15/2022</date>

Restricted stock — 01/15/2021 1,861 shares grant date <date>01/15/2021</date>

Restricted stock — 01/15/2023 1,956 shares grant date <date>01/15/2023</date>

Restricted stock — 02/23/2023 1,900 shares grant date <date>02/23/2023</date>

Restricted stock — 02/01/2024 1,775 shares grant date <date>02/01/2024</date>

Key Terms

Restricted Stock, Equity Compensation, Form 144

3 terms

Restricted Stock financial

"Common Stock | 01/15/2022 | Restricted Stock | Issuer"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Equity Compensation financial

"Equity Compensation Common Stock | 01/15/2021"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the IONS Form 144 disclose about the securities to be sold?

The Form 144 lists restricted stock awards and quantities. It shows grants of 3,110, 1,861, 1,956, 1,900 and 1,775 shares tied to dates between 01/15/2021 and 02/01/2024. It is a notice of proposed sale activity.

Are the listed IONS shares already sold or still proposed for sale?

The filing is a Form 144 notice, which reports proposed sales by an affiliate rather than completed transactions. The excerpt lists the awards and quantities but does not record execution or settlement details for any sale dates.

Do the IONS Form 144 entries specify who receives proceeds from sales?

The excerpt does not state proceeds recipients or use of proceeds. It identifies the instrument as Restricted Stock and links amounts to equity compensation grant dates, without describing cash‑flow treatment in this excerpt.

What grant dates and share amounts are listed in the IONS excerpt?

The excerpt lists these restricted stock grants and amounts: 01/15/2021 — 1,861 shares; 01/15/2022 — 3,110 shares; 01/15/2023 — 1,956 shares; 02/23/2023 — 1,900 shares; 02/01/2024 — 1,775 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 06:53 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001791058
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	Swayze Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	10602	839287.00	165262556	06/25/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2022	Restricted Stock	Issuer			3110	01/15/2022	Equity Compensation
Common Stock	01/15/2021	Restricted Stock	Issuer			1861	01/15/2021	Equity Compensation
Common Stock	01/15/2023	Restricted Stock	Issuer			1956	01/15/2023	Equity Compensation
Common Stock	02/23/2023	Restricted Stock	Issuer			1900	02/23/2023	Equity Compensation
Common Stock	02/01/2024	Restricted Stock	Issuer			1775	02/01/2024	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	06/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ James Weimer, as a duly authorized representative of STIFEL, as attorney-in-fact for Eric Swayze
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)